| Predicate |
Object |
| contentType |
Research Support, N.I.H., Extramural|Journal Article |
| endingPage |
1284 |
| issn |
1387-2877
1875-8908 |
| issueIdentifier |
4 |
| pageRange |
1277-1284 |
| publicationName |
Journal of Alzheimer's disease : JAD |
| startingPage |
1277 |
| hasFundingAgency |
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c9715a34c9ccde7ccc72cadee3277b94
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a1ebfe17b0713ecaf89801f0370c078d |
| isSupportedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_0bc3b0d7644e515470d7de37b1a0bc59
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_073d3514b0691b2cbb989d19899a0143 |
| bibliographicCitation |
Volloch V, Rits-Volloch S. Effect of Lecanemab in Early Alzheimer's Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective. J Alzheimers Dis. 2023;93(4):1277–84. PMID: 37212119; PMCID: PMC10357217. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89ab7900f369e3e67e1f69860d03faf8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b133978c6d5b530e9503275d718fc3a6 |
| date |
2023-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/PMC10357217
https://doi.org/10.3233/jad-230164
https://pubmed.ncbi.nlm.nih.gov/37212119 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1875-8908
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21942
https://portal.issn.org/resource/ISSN/1387-2877 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective |
| discusses |
http://id.nlm.nih.gov/mesh/M000758827
http://id.nlm.nih.gov/mesh/M0001047
http://id.nlm.nih.gov/mesh/M0455693
http://id.nlm.nih.gov/mesh/M0024786 |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11385
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6852 |